CAH Cardinal Health, Inc. Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 5, 2026 10-K/10-Q Aug 11, 2026CAH Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
CAH Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| April 23, 2001 | 3-for-2 | Forward |
| Nov. 2, 1998 | 3-for-2 | Forward |
| Dec. 17, 1996 | 3-for-2 | Forward |
| July 1, 1994 | 5-for-4 | Forward |
| Oct. 1, 1991 | 5-for-4 | Forward |
| Oct. 1, 1990 | 5-for-4 | Forward |
| Oct. 2, 1989 | 5-for-4 | Forward |
| Sept. 9, 1988 | 11-for-10 | Forward |
| Sept. 9, 1987 | 11-for-10 | Forward |
About Cardinal Health, Inc. Common Stock Company overview from Wikipedia
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CAH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | 32.95Y avg ≈29.4 | ≈29.4 | 22.9 | Overvalued | |
| PEG Ratio | ≈1.2 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CAH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 3.8%5Y avg ≈3.5% | ≈3.5% | 4.3% | Weak | |
| Operating Margin (TTM) | 1.0%5Y avg ≈0.52% | ≈0.52% | 1.1% | In line | |
| EBITDA Margin (TTM) | 1.4%5Y avg ≈0.88% | ≈0.88% | 1.3% | In line | |
| Pretax Margin (TTM) | 0.86%5Y avg ≈0.44% | ≈0.44% | 1.0% | Below avg | |
| Net Profit Margin (TTM) | 0.67%5Y avg ≈0.27% | ≈0.27% | 0.63% | In line | |
| ROA | 3.1%5Y avg ≈1.3% | ≈1.3% | 3.1% | In line | |
| ROE | -60.5%5Y avg ≈-65.5% | ≈-65.5% | -4.6% | Weak | |
| ROIC | -71.1%5Y avg ≈-13.6% | ≈-13.6% | 12.2% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CAH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 0.95Y avg ≈1.0 | ≈1.0 | 0.9 | Low liquidity | |
| Quick Ratio | 0.45Y avg ≈0.5 | ≈0.5 | 0.5 | Low liquidity | |
| Interest Coverage | 7.55Y avg ≈9.3 | ≈9.3 | 5.9 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CAH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 14.2%5Y avg ≈9.5% | ≈9.5% | · | · | |
| Revenue CAGR 3Y | 7.4%5Y avg ≈9.1% | ≈9.1% | · | · | |
| Revenue CAGR 5Y | 9.4% | · | · | · | |
| EPS YoY | 12.1%5Y avg ≈91.0% | ≈91.0% | · | · | |
| Net Income YoY | 9.8%5Y avg ≈83.7% | ≈83.7% | · | · | |
| EPS CAGR 3Y | 79.0% | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | CAH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 4.65Y avg ≈4.6 | ≈4.6 | 4.5 | Top tier | |
| Inventory Turnover | 14.35Y avg ≈13.2 | ≈13.2 | 15.7 | Weak | |
| Receivables Turnover | 18.85Y avg ≈18.6 | ≈18.6 | 13.1 | Top tier | |
| Revenue / Employee | ≈$4.3M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Oct 1, 2026 | $0.52 | USD | ≈0.89% |
| Jul 1, 2026 | $0.52 | USD | ≈0.86% |
| Apr 1, 2026 | $0.51 | USD | ≈0.96% |
| Jan 2, 2026 | $0.51 | USD | ≈0.99% |
| Oct 1, 2025 | $0.51 | USD | ≈1.3% |
| Jul 1, 2025 | $0.51 | USD | ≈1.2% |
| Apr 1, 2025 | $0.51 | USD | ≈1.5% |
| Jan 2, 2025 | $0.51 | USD | ≈1.7% |
| Oct 1, 2024 | $0.51 | USD | ≈1.8% |
| Jul 1, 2024 | $0.51 | USD | ≈2.1% |
| Mar 28, 2024 | $0.50 | USD | ≈1.8% |
| Dec 29, 2023 | $0.50 | USD | ≈2.0% |
| Oct 2, 2023 | $0.50 | USD | ≈2.3% |
| Jun 30, 2023 | $0.50 | USD | ≈2.1% |
| Mar 31, 2023 | $0.50 | USD | ≈2.6% |
| Dec 30, 2022 | $0.50 | USD | ≈2.6% |
| Sep 30, 2022 | $0.50 | USD | ≈3.0% |
| Jun 30, 2022 | $0.50 | USD | ≈3.8% |
| Mar 31, 2022 | $0.49 | USD | ≈3.5% |
| Dec 31, 2021 | $0.49 | USD | ≈3.8% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Dec. 31, 2026 | Aug 11, 2026 | $2.91 | $2.44 | 19.1% |
| June 30, 2026 | $2.60 | $2.44 | 6.4% | |
| March 31, 2026 | $3.17 | $2.82 | 12.6% | |
| Dec. 31, 2025 | $2.63 | $2.40 | 9.4% | |
| Sept. 30, 2025 | $2.55 | $2.20 | 15.9% | |
| June 30, 2025 | $2.08 | $2.06 | 1.1% | |
| March 31, 2025 | $2.35 | $2.19 | 7.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
Balance Sheet
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
Cash Flow
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
Profitability
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
Liquidity & Solvency
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
Efficiency
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
Per Share
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $1072.78 | $919.74 | $918.33 | $782.49 | $650.05 | $552.61 | $521.92 | $483.50 | $434.31 | $406.18 | $368.32 | $306.06 | |
| Cash Flow / Share | $21.83 | $9.90 | $15.23 | $10.84 | $11.19 | $8.26 | $6.69 | $9.04 | $8.79 | $3.70 | $9.00 | $7.58 | |
| Dividend Paid / Share | $2.04 | $2.02 | $2.00 | $1.98 | $1.96 | $1.94 | $1.92 | $1.91 | $1.85 | $1.80 | $1.55 | $1.37 | |
| EPS (TTM) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 |
Growth Rates
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
Income Statement
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | · | 235,000,000 | 236,000,000 | 238,000,000 | · | 240,000,000 | 242,000,000 | 243,000,000 | · | 243,000,000 | 245,000,000 | 249,000,000 | · | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | · | 236,000,000 | 237,000,000 | 239,000,000 | · | 241,000,000 | 243,000,000 | 245,000,000 | · | 245,000,000 | 246,000,000 | 249,000,000 | · | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
Balance Sheet
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
Cash Flow
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
Profitability
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
Liquidity & Solvency
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
Efficiency
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
Per Share
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $258.22 | $276.91 | $267.82 | · | $227.71 | $227.42 | $213.38 | · | $224.13 | $233.52 | $219.05 | · | $195.69 | $197.20 | $181.70 | |
| Cash Flow / Share | · | · | · | $4.07 | · | · | · | $-6.72 | · | · | · | $2.18 | · | · | · | $0.08 | |
| Dividend / Share | · | $0.51 | $0.51 | $0.51 | · | $0.51 | $0.51 | $0.51 | · | $0.50 | $0.50 | $0.50 | · | $0.50 | $0.50 | $0.50 |
Valuation (TTM)
| Metric | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $250.74B | $244.67B | $234.31B | · | $222.29B | $222.28B | $224.45B | · | $220.38B | $216.01B | $210.04B | · | $198.62B | $192.96B | $186.95B | |
| Net Income TTM | · | $1.55B | $1.66B | $1.59B | · | $1.56B | $1.31B | $1.28B | · | $622M | $726M | $281M | · | $519M | $-1.24B | $-1.11B | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% | |
| Annual Payout | · | $491M | $495M | $495M | · | $496M | $494M | $496M | · | $503M | $509M | $514M | · | $533M | $541M | $552M |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| Gross Margin % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| Operating Margin % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M |
| Diluted EPS | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
Institutional owners (13F) 1,605 filers · $54.4B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 156 (-26 vs prior Q) | 81 (-19 vs prior Q) | 530 (-24 vs prior Q) | 574 (+58 vs prior Q) | +7.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6,461,178,523 | 31,441,258 | 11.88% | Shares |
| BlackRock, Inc. | $6,293,114,912 | 26,490,633 | 11.57% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,632,811,706 | 15,292,186 | 6.68% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $3,530,205,977 | 14,860,271 | 6.49% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3,258,822,899 | 13,717,894 | 5.99% | Shares |
| STATE STREET CORP | $2,842,909,265 | 11,967,121 | 5.23% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,531,751,894 | 6,472,810 | 2.82% | Shares |
| Invesco Ltd. | $1,126,646,236 | 4,742,576 | 2.07% | Shares |
| MORGAN STANLEY | $1,098,793,649 | 4,625,329 | 2.02% | Shares |
| WCM INVESTMENT MANAGEMENT, LLC | $971,445,537 | 4,112,461 | 1.79% | Shares |
| NORGES BANK | $885,248,810 | 3,726,422 | 1.63% | Shares |
| BANK OF AMERICA CORP /DE/ | $689,065,528 | 2,900,596 | 1.27% | Shares |
| NORTHERN TRUST CORP | $681,536,598 | 2,868,903 | 1.25% | Shares |
| JPMORGAN CHASE & CO | $630,412,357 | 2,668,749 | 1.16% | Shares |
| GOLDMAN SACHS GROUP INC | $566,588,458 | 2,385,033 | 1.04% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $499,624,076 | 2,103,149 | 0.92% | Shares |
| FMR LLC | $490,857,853 | 2,066,248 | 0.90% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $490,754,373 | 2,322,438 | 0.90% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $469,793,667 | 1,977,579 | 0.86% | Shares |
| Legal & General Group Plc | $438,869,762 | 1,847,406 | 0.81% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $411,645,774 | 1,732,808 | 0.76% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $369,172,278 | 1,554,017 | 0.68% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $315,702,986 | 1,328,940 | 0.58% | Shares |
| AMERIPRISE FINANCIAL INC | $311,391,613 | 1,310,794 | 0.57% | Shares |
| NORDEA INVESTMENT MANAGEMENT AB | $308,748,216 | 1,297,534 | 0.57% | Shares |
| Bank of New York Mellon Corp | $308,639,982 | 1,299,209 | 0.57% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $281,612,012 | 1,185,468 | 0.52% | Shares |
| Robeco Institutional Asset Management B.V. | $258,918,781 | 1,089,909 | 0.48% | Shares |
| DEUTSCHE BANK AG\ | $238,933,097 | 1,005,780 | 0.44% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $230,523,823 | 970,390 | 0.42% | Shares |
| JANE STREET GROUP, LLC | $225,610,732 | 949,700 | 0.41% | Put option |
| Man Group plc | $222,013,123 | 934,556 | 0.41% | Shares |
| WELLS FARGO & COMPANY/MN | $219,711,690 | 924,868 | 0.40% | Shares |
| UBS Group AG | $218,780,954 | 920,950 | 0.40% | Shares |
| Amundi | $211,809,683 | 891,605 | 0.39% | Shares |
| Nuveen, LLC | $211,731,009 | 891,274 | 0.39% | Shares |
| RAYMOND JAMES FINANCIAL INC | $203,800,043 | 857,888 | 0.37% | Shares |
| ProShare Advisors LLC | $197,187,154 | 830,052 | 0.36% | Shares |
| ROYAL BANK OF CANADA | $185,518,000 | 780,931 | 0.34% | Shares |
| BARCLAYS PLC | $177,344,480 | 746,525 | 0.33% | Shares |
| FEDERATED HERMES, INC. | $176,399,992 | 742,549 | 0.32% | Shares |
| SEI INVESTMENTS CO | $173,413,944 | 729,965 | 0.32% | Shares |
| JANE STREET GROUP, LLC | $169,712,864 | 714,400 | 0.31% | Call option |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $163,869,121 | 693,714 | 0.30% | Shares |
| Allianz Asset Management GmbH | $163,833,492 | 689,651 | 0.30% | Shares |
| Swedbank AB | $159,718,953 | 672,331 | 0.29% | Shares |
| Swiss National Bank | $157,644,816 | 663,600 | 0.29% | Shares |
| JANUS HENDERSON GROUP PLC | $155,390,858 | 735,467 | 0.29% | Shares |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141,722,832 | 596,577 | 0.26% | Shares |
| 1832 Asset Management L.P. | $139,039,117 | 585,280 | 0.26% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 filings | June 5, 2014 | · | Initial filing | · | SEC |
| Undisclosed reporting person | July 2, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | May 28, 2004 | · | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 84 insiders · 45 officers · 37 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jason M. Hollar | Chief Executive Officer | Aug. 19, 2026 S | 190,603 | 0 | 10 | $-29,375,516 |
| Deborah Weitzman | CEO, PSS Segment | Aug. 18, 2026 S | 77,901 | 0 | 3 | $-1,731,524 |
| Stephen M Mason | CEO, GMPD Segment | Aug. 18, 2026 S | 18,061 | 0 | 4 | $-8,274,118 |
| Michael C Kaufmann | CEO | Aug. 15, 2022 M | 601,065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | Aug. 15, 2022 F | 105,699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | Aug. 15, 2019 F | 61,387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | Sept. 15, 2017 F | 146,503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | Feb. 27, 2012 M | 89,204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | Sept. 1, 2009 A | 238,635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | Sept. 2, 2007 F | 68,041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | May 16, 2006 M | 36,082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | Dec. 13, 2004 A | 14,400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | Aug. 18, 2026 S | 20,495 | 0 | 5 | $-10,451,104 |
| Jorge M Gomez | Chief Financial Officer | Nov. 8, 2018 F | 39,582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | Aug. 27, 2014 M | 67,190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | Nov. 17, 2003 A | · | 0 | 0 | $0 |
| George L Fotiades | President & COO | Jan. 15, 2003 P | 80,278 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | Aug. 19, 2026 S | 2,811 | 0 | 2 | $-546,473 |
| Michelle D. Greene | Chief Information Officer | Aug. 18, 2026 S | 10,330 | 0 | 6 | $-3,373,574 |
| Jessica L Mayer | Chief Legal/Compliance Officer | Aug. 18, 2026 S | 33,076 | 0 | 4 | $-6,952,485 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | Aug. 15, 2026 F | 11,757 | 0 | 0 | $0 |
| Ola M Snow | Chief Human Resources Officer | Dec. 1, 2025 F | 15,111 | 0 | 0 | $0 |
| Patricia M English | Chief Accounting Officer | Aug. 15, 2022 F | 9,000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | Aug. 15, 2022 F | 37,850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | Aug. 15, 2022 F | 44,491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | Aug. 15, 2020 F | 12,289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | Dec. 3, 2018 F | 126,301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | Aug. 31, 2018 F | 30,725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | Aug. 15, 2018 F | 22,612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | Aug. 15, 2018 F | 502,630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | May 20, 2016 M | 31,585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | Nov. 30, 2015 G | 32,455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | Nov. 17, 2015 F | 16,760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | Nov. 7, 2014 M | 20,409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | Nov. 1, 2008 F | 50,886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | Sept. 26, 2008 A | 39,594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | Nov. 26, 2007 I | 1,740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | June 4, 2007 M | 8,573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | Sept. 2, 2006 F | 85,978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | Sept. 6, 2005 G | 55,382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | Sept. 2, 2005 A | 6,137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | Sept. 2, 2005 A | 4,607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | Feb. 17, 2005 G | 7,000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | Aug. 23, 2004 A | 2,462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | Feb. 24, 2004 M | 31,039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | Director | April 15, 2026 A | 28,645 | 0 | 1 | $-918,880 |
| Michelle Brennan | Director | Nov. 5, 2025 A | 8,086 | 0 | 0 | $0 |
| Robert Azelby | Director | Nov. 5, 2025 A | 4,085 | 0 | 0 | $0 |
| Nancy Killefer | Director | Nov. 5, 2025 A | 27,624 | 0 | 0 | $0 |
| Akhil Johri | Director | Nov. 5, 2025 A | 22,868 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | Director | Nov. 5, 2025 A | 2,116 | 0 | 0 | $0 |
| Sheri H. Edison | Director | Nov. 5, 2025 A | 14,848 | 0 | 0 | $0 |
| Christine Mundkur | Director | Nov. 5, 2025 A | 7,536 | 0 | 0 | $0 |
| Gregory B Kenny | Director | Nov. 5, 2025 A | 64,194 | 0 | 0 | $0 |
| Steven Barg | Director | Nov. 15, 2023 A | 4,739 | 0 | 0 | $0 |
| Sujatha Chandrasekaran | Director | Nov. 15, 2023 A | 4,739 | 0 | 0 | $0 |
| Bruce Downey | Director | Nov. 9, 2022 A | 53,929 | 0 | 0 | $0 |
| COX CARRIE SMITH | Director | Nov. 9, 2022 A | 41,631 | 0 | 0 | $0 |
| Dean A Scarborough | Director | Oct. 18, 2022 A | 11,138 | 0 | 0 | $0 |
| John H Weiland | Director | Nov. 11, 2021 A | 11,138 | 0 | 0 | $0 |
| Michael J Losh | Director | Oct. 15, 2021 A | 9,988 | 0 | 0 | $0 |
| Calvin Darden | Director | Nov. 9, 2020 A | 39,616 | 0 | 0 | $0 |
| Colleen F. Arnold | Director | Nov. 12, 2019 A | 35,103 | 0 | 0 | $0 |
| David J Anderson | Director | Jan. 16, 2018 A | 9,946 | 0 | 0 | $0 |
| David P King | Director | Nov. 8, 2017 A | 21,044 | 0 | 0 | $0 |
| Clayton M Jones | Director | May 8, 2017 S | 0 | 0 | 0 | $0 |
| NOTEBAERT RICHARD C | Director | March 3, 2015 M | 35,778 | 0 | 0 | $0 |
| John F Finn | Director | Nov. 5, 2014 A | 21,074 | 0 | 0 | $0 |
| Glenn Britt | Director | May 7, 2014 A | 18,314 | 0 | 0 | $0 |
| Jean G Spaulding | Director | Nov. 6, 2013 A | 17,182 | 0 | 0 | $0 |
| David W Raisbeck | Director | Nov. 2, 2011 A | 17,075 | 0 | 0 | $0 |
| James J Mongan MD | Director | Nov. 3, 2010 A | 7,150 | 0 | 0 | $0 |
| Philip L Francis | Director | Sept. 1, 2009 D | 1,021 | 0 | 0 | $0 |
| John B Mccoy | Director | Nov. 5, 2008 A | 2,721 | 0 | 0 | $0 |
| Robert D Walter | Director | Oct. 6, 2008 M | 1,531,235 | 0 | 0 | $0 |
| Matthew D Walter | Director | Jan. 7, 2008 G | 2,232 | 0 | 0 | $0 |
| Robert L Gerbig | Director | Feb. 12, 2007 M | 66,218 | 0 | 0 | $0 |
| John F Havens | Director | Nov. 8, 2006 A | 30,973 | 0 | 0 | $0 |
| David Bing | Director | Aug. 3, 2005 A | 3,669 | 0 | 0 | $0 |
| Robert W Musslewhite | · | Nov. 5, 2025 A | 2,116 | 0 | 0 | $0 |
| David C Evans | · | Nov. 5, 2025 A | 15,373 | 0 | 0 | $0 |
| David L Schlotterbeck | · | Sept. 1, 2009 D | 61,523 | 0 | 0 | $0 |
| Michael D Ohalleran | · | Sept. 1, 2009 D | 8,458 | 0 | 0 | $0 |
| George N Conrades | · | Nov. 5, 2008 A | 2,653 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 148 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PEZ · Invesco Exchange-Traded Fund Trust | 5.29% | 4,961 SH | Oct. 2, 2026 | Daily |
| FXG · First Trust Exchange-Traded AlphaDE… | 3.15% | 31,414 NS | July 31, 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 2.97% | 12,009 NS | July 31, 2026 | N-PORT |
| IYK · iShares Trust | 2.56% | 150,019 SH | Sept. 11, 2026 | Daily |
| NUMV · Nushares ETF Trust | 2.30% | 44,435 NS | July 31, 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 2.09% | 14,948 SH | Oct. 2, 2026 | Daily |
| SMRI · EA Series Trust | 1.84% | 51,638 NS | July 31, 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.59% | 59,923 SH | Oct. 2, 2026 | Daily |
| NULV · Nushares ETF Trust | 1.53% | 145,860 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.51% | 597 NS | July 31, 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.49% | 228,600 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1.47% | 1,193,309 NS | July 31, 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 1.34% | 23,570 SH | Aug. 19, 2026 | Daily |
| UPSD · ETF Series Solutions | 1.31% | 6,646 NS | July 31, 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 1.25% | 527,725 SH | Oct. 2, 2026 | Daily |
| SRHQ · Elevation Series Trust | 1.20% | 11,056 NS | July 31, 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 1.11% | 6,347 SH | Oct. 2, 2026 | Daily |
| RPV · Invesco Exchange-Traded Fund Trust | 1.10% | 79,806 SH | Oct. 2, 2026 | Daily |
| ESMV · iShares Trust | 1.06% | 350 SH | Sept. 11, 2026 | Daily |
| PDP · Invesco Exchange-Traded Fund Trust | 1.06% | 67,986 SH | Oct. 2, 2026 | Daily |
| VOE · VANGUARD INDEX FUNDS | 0.96% | 1,504,470 SH | Aug. 19, 2026 | Daily |
| ABFL · Abacus FCF ETF Trust | 0.92% | 21,099 NS | July 31, 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0.87% | 4,124 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.82% | 707,389 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.78% | 111,939 NS | July 31, 2026 | N-PORT |
| IWP · iShares Trust | 0.74% | 604,324 SH | Sept. 11, 2026 | Daily |
| LSEQ · Harbor ETF Trust | 0.70% | 468 NS | July 31, 2026 | N-PORT |
| IXJ · iShares Trust | 0.70% | 123,272 SH | Sept. 11, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.62% | 4,609 NS | July 31, 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.59% | 4,662 NS | July 31, 2026 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.55% | 31,604 NS | July 31, 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.54% | 5,075,476 SH | Aug. 19, 2026 | Daily |
| FTLS · First Trust Exchange-Traded Fund III | 0.51% | 54,815 NS | July 31, 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.47% | 19,654 SH | Oct. 2, 2026 | Daily |
| LGDX · Tidal Trust III | 0.44% | 2,735 NS | July 31, 2026 | N-PORT |
| EVUS · iShares Trust | 0.43% | 6,970 SH | Sept. 11, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.43% | 108,869 NS | July 31, 2026 | N-PORT |
| IMCG · iShares Trust | 0.42% | 71,722 SH | Sept. 11, 2026 | Daily |
| QLC · FlexShares Trust | 0.42% | 18,368 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.41% | 959,539 SH | Sept. 11, 2026 | Daily |
| LCOW · Pacer Funds Trust | 0.40% | 454 NS | July 31, 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.39% | 11,919 NS | July 31, 2026 | N-PORT |
| IMCB · iShares Trust | 0.39% | 27,470 SH | Sept. 11, 2026 | Daily |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 7,324 NS | July 31, 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.36% | 5,200 NS | July 31, 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 7,082 NS | July 31, 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.35% | 445,000 | Oct. 2, 2026 | Daily |
| IMCV · iShares Trust | 0.35% | 16,989 SH | Sept. 11, 2026 | Daily |
| ACWV · iShares, Inc. | 0.33% | 46,363 SH | Sept. 11, 2026 | Daily |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.32% | 9,479,000 | Oct. 2, 2026 | Daily |
| XOEF · iShares Trust | 0.31% | 293 SH | Sept. 11, 2026 | Daily |
| IWS · iShares Trust | 0.29% | 189,265 SH | Sept. 11, 2026 | Daily |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.28% | 30,714 NS | July 31, 2026 | N-PORT |
| GLOF · iShares Trust | 0.28% | 2,389 SH | Sept. 11, 2026 | Daily |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.28% | 12,847,000 | Oct. 2, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.27% | 6,869 NS | July 31, 2026 | N-PORT |
| ESGU · iShares Trust | 0.26% | 200,383 SH | Sept. 11, 2026 | Daily |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.26% | 17,795 NS | July 31, 2026 | N-PORT |
| NULC · Nushares ETF Trust | 0.26% | 796 NS | July 31, 2026 | N-PORT |
| CATH · Global X Funds | 0.26% | 14,490 NS | July 31, 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0.25% | 7,970,000 | Oct. 2, 2026 | Daily |
| DYNF · BlackRock ETF Trust | 0.25% | 443,705 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.25% | 21,158 SH | Aug. 19, 2026 | Daily |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.24% | 1,323,136 SH | Aug. 19, 2026 | Daily |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0.23% | 233,192 SH | Oct. 2, 2026 | Daily |
| VYM · VANGUARD WHITEHALL FUNDS | 0.23% | 934,496 SH | Aug. 19, 2026 | Daily |
| ESG · FlexShares Trust | 0.23% | 1,320 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.22% | 3,988 SH | Sept. 11, 2026 | Daily |
| LRGF · iShares Trust | 0.22% | 33,556 SH | Sept. 11, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 0.21% | 2,225,442 SH | Aug. 19, 2026 | Daily |
| VFMF · VANGUARD WELLINGTON FUND | 0.21% | 6,281 SH | Aug. 19, 2026 | Daily |
| EUSA · iShares, Inc. | 0.20% | 16,612 SH | Sept. 11, 2026 | Daily |
| PFM · Invesco Exchange-Traded Fund Trust | 0.20% | 6,670 SH | Oct. 2, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 813,183 SH | Oct. 2, 2026 | Daily |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.19% | 53,931 SH | Aug. 19, 2026 | Daily |
| IVE · iShares Trust | 0.19% | 388,621 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.18% | 205,310 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.18% | 6,098 SH | Oct. 2, 2026 | Daily |
| IQSU · New York Life Investments ETF Trust | 0.17% | 2,435 NS | July 31, 2026 | N-PORT |
| CHRI · Global X Funds | 0.16% | 57 NS | July 31, 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.16% | 4,467,000 | Oct. 2, 2026 | Daily |
| DSI · iShares Trust | 0.16% | 35,796 SH | Sept. 11, 2026 | Daily |
| EGLE · Global X Funds | 0.13% | 12 NS | July 31, 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0.12% | 6 NS | July 31, 2026 | N-PORT |
| LQAI · Exchange Listed Funds Trust | 0.12% | 12 NS | July 31, 2026 | N-PORT |
| DGRO · iShares Trust | 0.12% | 217,268 SH | Sept. 11, 2026 | Daily |
| VFVA · VANGUARD WELLINGTON FUND | 0.11% | 3,797 SH | Aug. 19, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.10% | 7,530 SH | Oct. 2, 2026 | Daily |
| TOPC · iShares Trust | 0.10% | 144 SH | Sept. 11, 2026 | Daily |
| ACVF · ETF Opportunities Trust | 0.10% | 675 NS | July 31, 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.10% | 52,911 SH | Aug. 19, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.10% | 9,417 NS | July 31, 2026 | N-PORT |
| ILCG · iShares Trust | 0.10% | 12,549 SH | Sept. 11, 2026 | Daily |
| XVV · iShares Trust | 0.09% | 2,689 SH | Sept. 11, 2026 | Daily |
| USMV · iShares Trust | 0.09% | 91,385 SH | Sept. 11, 2026 | Daily |
| VOO · VANGUARD INDEX FUNDS | 0.09% | 6,082,026 SH | Aug. 19, 2026 | Daily |
| VV · VANGUARD INDEX FUNDS | 0.09% | 273,537 SH | Aug. 19, 2026 | Daily |
| XRMI · Global X Funds | 0.09% | 194 NS | July 31, 2026 | N-PORT |
| XYLG · Global X Funds | 0.09% | 244 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.09% | 12,239 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.08% | 45,685 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.08% | 2,952,119 SH | Sept. 11, 2026 | Daily |
| PTLC · Pacer Funds Trust | 0.08% | 11,916 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.08% | 13 NS | July 31, 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.08% | 32,252 NS | July 31, 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0.08% | 21 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.08% | 4,535 SH | Sept. 11, 2026 | Daily |
| VOTE · TCW ETF Trust | 0.08% | 3,959 NS | July 31, 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.08% | 1,385 SH | Oct. 2, 2026 | Daily |
| BKLC · BNY Mellon ETF Trust | 0.08% | 19,424 NS | July 31, 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.08% | 40,564 SH | Oct. 2, 2026 | Daily |
| XTR · Global X Funds | 0.08% | 17 NS | July 31, 2026 | N-PORT |
| IWD · iShares Trust | 0.08% | 282,063 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.08% | 7,436,156 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.08% | 38,624 SH | Aug. 19, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.08% | 76,610 SH | Aug. 19, 2026 | Daily |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.08% | 169,890 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.08% | 19,715 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.08% | 913 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.08% | 162,672 SH | Sept. 11, 2026 | Daily |
| IYY · iShares Trust | 0.08% | 10,064 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.08% | 71,472 NS | July 31, 2026 | N-PORT |
| USCL · iShares Trust | 0.08% | 9,352 SH | Sept. 11, 2026 | Daily |
| SPUU · Direxion Shares ETF Trust | 0.08% | 884 NS | July 31, 2026 | N-PORT |
| IWF · iShares Trust | 0.08% | 402,774 SH | Sept. 11, 2026 | Daily |
| QDPL · Pacer Funds Trust | 0.08% | 5,627 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.08% | 32,168 SH | Oct. 2, 2026 | Daily |
| IWV · iShares Trust | 0.08% | 64,328 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.08% | 304,905 SH | Sept. 11, 2026 | Daily |
| ILCV · iShares Trust | 0.07% | 4,083 SH | Sept. 11, 2026 | Daily |
| TILT · FlexShares Trust | 0.07% | 6,802 NS | July 31, 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.07% | 183 SH | Oct. 2, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.07% | 9,717 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.07% | 1,627 NS | July 31, 2026 | N-PORT |
| TOK · iShares Trust | 0.07% | 656 SH | Sept. 11, 2026 | Daily |
| SPXL · Direxion Shares ETF Trust | 0.06% | 18,311 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.06% | 129,668 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.06% | 20,873 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.05% | 74,784 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.05% | 197,885 SH | Aug. 19, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.01% | 343 NS | July 31, 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0.00% | 40,400 | Sept. 30, 2026 | Daily |
| GTOS · Invesco Actively Managed Exchange-T… | 0.00% | 600 | Sept. 30, 2026 | Daily |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
CAH Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
15 analysts · 2026-10-02Mean target $270.33 +16.0%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.